GENI
Genius Sports Limited
GENI has slightly lower modeled downside risk, despite its lower overall score.
RDDT
Reddit, Inc.
RDDT has the edge over GENI overall, supported by stronger fundamentals and stronger modeled upside.
GENI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
GENI's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
RDDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
RDDT's revenue, profitability, cash flow and balance sheet are all currently healthy.
GENI PE Valuation
GENI has no meaningful PE right now: it lost money over the past year.
RDDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $99.55 | — |
| Current | 20x | $99.55 | — |
| Cheap | 35x | $171 | +72% |
| Fair | 46x | $228 | +129% |
| Expensive | 53x | $262 | +163% |
Historical ranges are pointers, not guarantees.
RDDT's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
GENI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect GENI's losses to grow, with revenue growing. However, they disagree widely on these estimates.
RDDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
RDDT has the edge over GENI on the outlook, with more favorable earnings and profitability expectations.
GENI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.68 | -$0.37 |
| Q1 2026 | -$0.61 | -$0.42 |
| Q4 2025 | -$0.43 | -$0.16 |
| Q3 2025 | -$0.47 | -$0.15 |
| Q2 2025 | -$0.31 | +$0.12 |
| Q1 2025 | -$0.19 | +$0.20 |
| Q4 2024 | -$0.27 | +$0.13 |
| Q3 2024 | -$0.32 | +$0.54 |
RDDT has the stronger earnings trend. Trailing diluted EPS is down 319% for GENI versus RDDT down 39%.
RDDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.32 | +29% |
| Q3 2024 | -$7.98 | -$7.17 |
| Q2 2024 | -$8.19 | -$7.15 |
| Q1 2024 | -$8.38 | -$7.25 |
| Q4 2023 | -$0.56 | +$0.41 |
| Q3 2023 | -$0.81 | -$0.02 |
| Q2 2023 | -$1.04 | -$0.48 |
| Q1 2023 | -$1.13 | -$0.48 |
| Q4 2022 | -$0.97 | -$0.19 |
RDDT has returned to profit: it earned $4.90 per share over the past year, after losing money the year before.
GENI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $195.5M | +65% |
| Q1 2026 | $188M | +31% |
| Q4 2025 | $240.5M | +37% |
| Q3 2025 | $166.3M | +38% |
| Q2 2025 | $118.7M | +24% |
| Q1 2025 | $144M | +20% |
| Q4 2024 | $175.5M | +38% |
| Q3 2024 | $120.2M | +18% |
GENI's revenue has grown year over year every quarter since late 2020: $196M last quarter, up 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -14% | +54 points |
| Q1 2026 | -16% | -1.6 points |
| Q4 2025 | -8.4% | -4.3 points |
| Q3 2025 | -14% | -8.8 points |
| Q2 2025 | -68% | -46 points |
| Q1 2025 | -14% | +6.1 points |
| Q4 2024 | -4.1% | +23 points |
| Q3 2024 | -5% | +3.7 points |
GENI's operating margin was −14% last quarter, up 54 points from the same quarter a year ago.
RDDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895M | +53% |
| Q2 2026 | $804.9M | +61% |
| Q1 2026 | $663.4M | +69% |
| Q4 2025 | $725.6M | +70% |
| Q3 2025 | $584.9M | +68% |
| Q2 2025 | $499.6M | +78% |
| Q1 2025 | $392.4M | +61% |
| Q4 2024 | $427.7M | +71% |
RDDT has the edge over GENI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +5.5 points |
| Q2 2026 | 29% | +15 points |
| Q1 2026 | 28% | +27 points |
| Q4 2025 | 32% | +20 points |
| Q3 2025 | 24% | +22 points |
| Q2 2025 | 14% | +25 points |
| Q1 2025 | 1% | +244 points |
| Q4 2024 | 12% | +11 points |
RDDT has the edge over GENI on profitability, with a higher operating margin.
GENI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$87M | -$67.8M |
| Q1 2026 | -$68.2M | -$20M |
| Q4 2025 | $69.6M | -0.4% |
| Q3 2025 | $19.1M | +$41.8M |
| Q2 2025 | -$19.2M | -$16.5M |
| Q1 2025 | -$48.3M | -$21.3M |
| Q4 2024 | $69.9M | +559% |
| Q3 2024 | -$22.7M | -7493% |
GENI has burned cash in most quarters: −$66M over the past year, against −$20M the year before.
RDDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $362.6M | +98% |
| Q2 2026 | $260.7M | +135% |
| Q1 2026 | $311.2M | +146% |
| Q4 2025 | $263.6M | +196% |
| Q3 2025 | $183.1M | +161% |
| Q2 2025 | $110.8M | +308% |
| Q1 2025 | $126.6M | +333% |
| Q4 2024 | $89.2M | +$111.2M |
RDDT has the edge over GENI on cash generation, producing positive trailing cash flow while its opponent burns cash.
GENI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +9.5M shares |
| 1 year | +10% | +25.7M shares |
| 3 years | +34% | +70.4M shares |
| 5 years | +85% | +128M shares |
| Available history | +56% | +100M shares |
GENI has 279M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GENI hasn't bought back shares in the past year.
RDDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -169K shares |
| 1 year | -0.4% | -868K shares |
| 3 years | +24% | +38.5M shares |
| 5 years | +24% | +38.5M shares |
RDDT has the edge over GENI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $234.6M |
| Q1 2026 | $5M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $4.2M |
| Q4 2022 | — |
GENI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -12.5x | Net Cash |
| Q4 2024 | -6.3x | Net Cash |
| Q1 2024 | -7.5x | Net Cash |
| Q4 2023 | -15.2x | Net Cash |
| Q1 2021 | 4.3x | High |
| Q4 2020 | 5.5x | High |
| Q3 2020 | 9.1x | High |
GENI has more cash than debt.
RDDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -3.3x | Net Cash |
| Q2 2025 | -5.0x | Net Cash |
| Q1 2025 | -13.1x | Net Cash |
RDDT has more cash than debt.
GENI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 23.4 | Neutral |
GENI's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
RDDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 6.5 | Oversold |
RDDT's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
GENI PE vs Communication Services Sector
GENI has no meaningful PE right now: it lost money over the past year.
RDDT PE vs Communication Services Sector
| Metric | RDDT | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 16x | 23% above |
| PE % | 5 | 23 | 18 pts below |
RDDT is trading at 20x earnings, a 23% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
GENI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.28 | 2.9% below |
| 20 week MA | $6.73 | 9.4% below |
| 50 week MA | $6.77 | 9.9% below |
| 100 week MA | $8.60 | 29% below |
| 200 week MA | $7.35 | 17% below |
RDDT has stronger trend alignment. GENI is above 0 of 5 weekly averages versus RDDT above 0 of 4.
RDDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.6 | 24% below |
| 20 week MA | $151.7 | 34% below |
| 50 week MA | $165.0 | 40% below |
| 100 week MA | $167.1 | 40% below |
RDDT is in a downtrend: it's below all four of its weekly moving averages, and 40% below its 100-week average.
GENI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $16.6 | +68% |
| 2021 | $16.6 | $7.61 | -54% |
| 2022 | $7.61 | $3.27 | -57% |
| 2023 | $3.27 | $6.18 | +89% |
| 2024 | $6.18 | $8.75 | +42% |
| 2025 | $8.75 | $10.9 | +24% |
| 2026 YTD | $10.9 | $6.10 | -44% |
GENI has the edge over RDDT on returns for 2026, with the stronger performance.
RDDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $46.0 | $173.5 | +277% |
| 2025 | $173.5 | $225.8 | +30% |
| 2026 YTD | $225.8 | $99.6 | -56% |
RDDT has finished every year since 2024 higher, and it's down 56% so far in 2026.